CXCL10 is one of the candidate markers which have been suggested to distinguish the individuals with LTBI or TB patients from uninfected controls [14] and ESAT-6 induced CXCL10 production was superior to IFN-γ in both specificity and sensitivity for detecting LTBI in rheumatoid arthritis patients who received anti-TNF-α treatment [15]. The gene discussed is CXCL10; the disease is rheumatoid arthritis.